1. Home
  2. NVR vs INSM Comparison

NVR vs INSM Comparison

Compare NVR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVR
  • INSM
  • Stock Information
  • Founded
  • NVR 1980
  • INSM 1988
  • Country
  • NVR United States
  • INSM United States
  • Employees
  • NVR N/A
  • INSM N/A
  • Industry
  • NVR Homebuilding
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVR Consumer Discretionary
  • INSM Health Care
  • Exchange
  • NVR Nasdaq
  • INSM Nasdaq
  • Market Cap
  • NVR 21.1B
  • INSM 19.1B
  • IPO Year
  • NVR N/A
  • INSM 2000
  • Fundamental
  • Price
  • NVR $7,795.06
  • INSM $103.95
  • Analyst Decision
  • NVR Buy
  • INSM Strong Buy
  • Analyst Count
  • NVR 4
  • INSM 17
  • Target Price
  • NVR $8,783.33
  • INSM $109.20
  • AVG Volume (30 Days)
  • NVR 20.6K
  • INSM 4.1M
  • Earning Date
  • NVR 07-23-2025
  • INSM 08-07-2025
  • Dividend Yield
  • NVR N/A
  • INSM N/A
  • EPS Growth
  • NVR N/A
  • INSM N/A
  • EPS
  • NVR 474.93
  • INSM N/A
  • Revenue
  • NVR $10,717,672,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • NVR N/A
  • INSM $28.17
  • Revenue Next Year
  • NVR $0.13
  • INSM $120.09
  • P/E Ratio
  • NVR $16.41
  • INSM N/A
  • Revenue Growth
  • NVR 5.86
  • INSM 20.77
  • 52 Week Low
  • NVR $6,562.85
  • INSM $60.40
  • 52 Week High
  • NVR $9,964.77
  • INSM $106.83
  • Technical
  • Relative Strength Index (RSI)
  • NVR 59.71
  • INSM 66.75
  • Support Level
  • NVR $7,371.39
  • INSM $101.55
  • Resistance Level
  • NVR $8,042.50
  • INSM $103.74
  • Average True Range (ATR)
  • NVR 176.83
  • INSM 2.58
  • MACD
  • NVR 23.12
  • INSM -0.49
  • Stochastic Oscillator
  • NVR 67.79
  • INSM 86.11

About NVR NVR Inc.

NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: